

Mar. 13. 2008 3:28PM

Farsight Patents (650)-679-9596

No. 0046 P. 10

01/25/2008 14:00

6507809030

FARSIGHT/HIGH TECHNI

PAGE 07/08

RECEIVED
CENTRAL FAX CENTER

JAN 25 2008

Patricia Dkt No. ALE 053.16
USSN: 10/645,293

RECEIVED
CENTRAL FAX CENTER

MAR 13 2008

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)	
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.	
<i>Yang R. Fabian</i>	25 January 2008
Signature	Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: PEERY, John, et al.	Confirmation No.: 7202
Serial No.: 10/645,293	Art Unit: 1618
Filing Date: 20 August 2003	Examiner: Ebrahim, N.G.
Title: SUSTAINED DELIVERY OF AN ACTIVE AGENT USING AN IMPLANTABLE SYSTEM	

**AUTHORIZATION TO CHARGE OR CREDIT DEPOSIT ACCOUNT AND
BLANKET PETITION FOR EXTENSION OF TIME**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

If a paper is untimely filed in this application or any continued prosecution application derived therefrom by applicant(s) or his/her/their representative, the Commissioner is hereby petitioned under 37 CFR § 1.136(a) for the minimum extension of time required to make said paper timely. In the event a petition for extension of time is made under the provisions of this paragraph, the Commissioner is hereby requested to charge any fee required under 37 CFR § 1.17(a)-(d) to Deposit Account No. 304212 (please reference docket number ALE 053.16). This, however, is not authorization to pay the Issue Fee.

1

PAGE 7/8 * RCVD AT 1/25/2008 5:13:35 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:6507809030 * DURATION (mm-ss):01-38

PAGE 10/11 * RCVD AT 3/13/2008 7:27:18 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/40 * DNIS:2738300 * CSID:650 679 9596 * DURATION (mm-ss):03-36

RECEIVED
CENTRAL FAX CENTER

JAN 25 2008

Intarcia Dkt No. ALE 053.16

USSN: 10/645,293

PATENT

If a paper is concurrently or subsequently filed in this application or any continued prosecution application derived therefrom by applicant(s) or his/her/their representative and a fee under 37 CFR §§ 1.16-1.17 is required to effect any amendment, petition or other action requested in said paper, the Commissioner is hereby requested to charge any deficiency in said fee, or credit any overpayment of said fee, to Deposit Account No. 504212. This, however, is not authorization to pay the Issue Fee.

RECEIVED
CENTRAL FAX CENTER

MAR 13 2008

Respectfully submitted,

Gary R Fabian

Dated: 25 January 2008

By :

Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicants

Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608
Phone: (510) 652-2600
Fax: (510) 652-2657